ASH 2023: Exploring Therapeutic Advancements for Chronic Lymphocytic Leukemia - Episode 6
Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.